
EquitySector - HealthcareVery High Risk
Direct
NAV (10-Apr-26)
Returns (Since Inception)
Fund Size
₹515 Cr
Expense Ratio
0.60%
ISIN
INF251K01VA5
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
27 Jun 2025
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-6.37%
— (Cat Avg.)
| Equity | ₹494.18 Cr | 95.92% |
| Others | ₹21.01 Cr | 4.08% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹52.72 Cr | 10.23% |
| Lupin Ltd | Equity | ₹32.39 Cr | 6.29% |
| Abbott India Ltd | Equity | ₹28.51 Cr | 5.53% |
| Torrent Pharmaceuticals Ltd | Equity | ₹27.43 Cr | 5.32% |
| Ipca Laboratories Ltd | Equity | ₹27.22 Cr | 5.28% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹23.3 Cr | 4.52% |
| Laurus Labs Ltd | Equity | ₹22.83 Cr | 4.43% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹22.71 Cr | 4.41% |
| AstraZeneca Pharma India Ltd | Equity | ₹20.19 Cr | 3.92% |
| SBI Life Insurance Co Ltd | Equity | ₹17.77 Cr | 3.45% |
| Emcure Pharmaceuticals Ltd | Equity | ₹17.32 Cr | 3.36% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹16.75 Cr | 3.25% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹16.69 Cr | 3.24% |
| Fortis Healthcare Ltd | Equity | ₹15.9 Cr | 3.09% |
| Gland Pharma Ltd | Equity | ₹15.26 Cr | 2.96% |
| ICICI Prudential Life Insurance Co Ltd | Equity | ₹14.78 Cr | 2.87% |
| Dr. Lal PathLabs Ltd | Equity | ₹13.12 Cr | 2.55% |
| Aurobindo Pharma Ltd | Equity | ₹13.04 Cr | 2.53% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹12.03 Cr | 2.33% |
| Rainbow Childrens Medicare Ltd | Equity | ₹11.63 Cr | 2.26% |
| Divi's Laboratories Ltd | Equity | ₹10.05 Cr | 1.95% |
| Ajanta Pharma Ltd | Equity | ₹9.82 Cr | 1.91% |
| Acutaas Chemicals Ltd | Equity | ₹8.96 Cr | 1.74% |
| Medplus Health Services Ltd | Equity | ₹8.4 Cr | 1.63% |
| Dr Reddy's Laboratories Ltd | Equity | ₹8.16 Cr | 1.58% |
| Nephrocare Health Services Ltd | Equity | ₹7.6 Cr | 1.48% |
| Poly Medicure Ltd | Equity | ₹7.15 Cr | 1.39% |
| Inventurus Knowledge Solutions Ltd | Equity | ₹6.64 Cr | 1.29% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.4 Cr | 1.24% |
| Mankind Pharma Ltd | Equity | ₹6.02 Cr | 1.17% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹5.77 Cr | 1.12% |
| Cipla Ltd | Equity | ₹5.51 Cr | 1.07% |
| Metropolis Healthcare Ltd | Equity | ₹5.43 Cr | 1.05% |
| Net Receivables / (Payables) | Cash | ₹-2.29 Cr | 0.44% |
Large Cap Stocks
29.18%
Mid Cap Stocks
32.43%
Small Cap Stocks
34.30%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹452.68 Cr | 87.87% |
| Financial Services | ₹32.55 Cr | 6.32% |
| Basic Materials | ₹8.96 Cr | 1.74% |
Standard Deviation
This fund
--
Cat. avg.
16.46%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.96
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.70
Higher the better

Since June 2025
ISIN INF251K01VA5 | Expense Ratio 0.60% | Exit Load 1.00% | Fund Size ₹515 Cr | Age 9 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹54,317 Cr
Address
Crescenzo, 7th Floor, G-Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments